Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May 1;45(4):174-180.
doi: 10.1097/MPH.0000000000002671. Epub 2023 Mar 20.

COVID-19 Infection and Outcomes in Newborn Screening Cohorts of Sickle Cell Trait and Sickle Cell Disease in Michigan and Georgia

Affiliations

COVID-19 Infection and Outcomes in Newborn Screening Cohorts of Sickle Cell Trait and Sickle Cell Disease in Michigan and Georgia

Susan T Paulukonis et al. J Pediatr Hematol Oncol. .

Abstract

The sickle cell mutation increases morbidity in those with sickle cell disease (SCD) and potentially sickle cell trait, impacting pulmonary, coagulation, renal, and other systems that are implicated in COVID-19 severity. There are no population-based registries for hemoglobinopathies, and they are not tracked in COVID-19 testing. We used COVID-19 test data from 2 states linked to newborn screening data to estimate COVID outcomes in people with SCD or trait compared with normal hemoglobin. We linked historical newborn screening data to COVID-19 tests, hospitalization, and mortality data and modeled the odds of hospitalization and mortality. Georgia's cohort aged 0 to 12 years; Michigan's, 0 to 33 years. Over 8% of those in Michigan were linked to positive COVID-19 results, and 4% in Georgia. Those with SCD showed significantly higher rates of COVID-19 hospitalization than the normal hemoglobin Black cohort, and Michigan had higher rates of mortality as well. Outcomes among those with the trait did not differ significantly from the normal hemoglobin Black group. People with SCD are at increased risk of COVID-19-related hospitalization and mortality and are encouraged to be vaccinated and avoid infection. Persons with the trait were not at higher risk of COVID-related severe outcomes.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

FIGURE 1
FIGURE 1
Study population linkages, COVID-19 infections, and newborn screening results, (A) Georgia and (B) Michigan*. *Probable cases are defined as at least 1 of the following: Meets clinical criteria AND epidemiologic linkage with no confirmatory laboratory testing performed for SARS-CoV-2. Meets presumptive laboratory evidence. Meets vital records criteria with no confirmatory laboratory evidence for SARS-CoV-2.
FIGURE 2
FIGURE 2
Crude and adjusted3 odd ratios for COVID-19 hospitalization and mortality among Black race individuals with (1) sickle cell disease or (2) sickle cell trait as compared with normal hemoglobin.1 Logistic models; there were no deaths among those with SCD or trait in Georgia.2 Logistic models with generalized estimating equations to account for reinfections.3 Adjusted for sex and age.

References

    1. Frydman GH, Boyer EW, Nazarian RM, et al. . Coagulation status and venous thromboembolism risk in African Americans: A potential risk factor in COVID-19. Clin Appl Thromb Hemost. 2020;26:1076029620943671. - PMC - PubMed
    1. Mucalo L, Brandow AM, Dasgupta M, et al. . Comorbidities are risk factors for hospitalization and serious COVID-19 illness in children and adults with sickle cell disease. Blood Adv. 2021;5:2717–2724. - PMC - PubMed
    1. Yurtsever N, Nandi V, Ziemba Y, et al. . Prognostic factors associated with COVID-19 related severity in sickle cell disease. Blood Cells Mol Dis. 2021;92:102627. - PMC - PubMed
    1. Payne AB, Schieve LA, Abe K, et al. . COVID-19 and Sickle Cell Disease-Related Deaths Reported in the United States. Public Health Rep. 2022;137:234–238. - PMC - PubMed
    1. Lee JX, Chieng WK, Lau SCD, et al. . COVID-19 and hemoglobinopathies: A systematic review of clinical presentations, investigations, and outcomes. Front Med (Lausanne). 2021;8:757510. - PMC - PubMed

Publication types